Management of Graves' ophthalmopathy

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 5, 2007, Pages 396-404

  Wiersinga, Wilmar M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Graves' ophthalmopathy; Hyperthyroidism; Smoking; Steroids; Surgery

Indexed keywords

ANGIOPEPTIN; ANTITHYROID AGENT; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IODINE 131; LONG ACTING DRUG; METHYLPREDNISOLONE; OCTREOTIDE; PREDNISONE; RADIOACTIVE IODINE; SOMATOSTATIN DERIVATIVE; STEROID; THYROID ANTIBODY; THYROID PEROXIDASE; THYROTROPIN; THYROTROPIN RECEPTOR;

CLINICAL TRIAL; DECOMPRESSION SURGERY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG PULSE THERAPY; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; LIVER FAILURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING; THYROIDECTOMY; THYROTROPIN RELEASE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISION;

ADULT; EYE DISEASES; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; OPHTHALMOLOGIC SURGICAL PROCEDURES; SMOKING; THYROID DISEASES;

EID: 34247463362     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0497     Document Type: Review

References (66)

1. Brokken LJ et al. (2003) Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease. J Clin Endocrinol Metab 88: 4135-4138
2. Gerding MN et al. (2000) Association of thyrotropin receptor autoantibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 52: 267-271
3. Eckstein AK et al. (2004) Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol 61: 612-619
4. Eckstein AK et al. (2006) TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470
5. Khoo DHC et al. (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9: 1175-1180
6. The European Group on Graves' Orbitopathy (EUGOGO) (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387-389
7. Dickinson AJ and Perros P (2001) Controversies in the clinical evaluation of active thyroid associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol 55: 283-303
8. Farid M et al. (2005) Psychological disturbance in Graves' ophthalmopathy. Arch Ophthalmol 123: 491-496
9. Kahaly GJ et al. (2005) Psychosocial morbidity of Graves' orbitopathy. Clin Endocrinol 63: 395-402
10. EUGOGO European Group on Graves' Orbitopathy [www.eugogo.org] (accessed 8 March 2007)
11. Terwee CB et al. (2001) Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QoL) after different treatments. Clin Endocrinol 54: 391-398
12. Wiersinga WM (2005) The philosophy of Graves' ophthalmopathy. Orbit 24: 165-171
13. Prummel MF and Wiersinga WM (1993) Smoking and risk of Graves' disease. JAMA 269: 479-482
14. Krassas GE et al. (2005) Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515-521
15. Bartalena L et al. (1998) Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 129: 632-635
16. Eckstein A et al. (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87: 773-776
17. Pfeilschifter J and Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol 45: 477-481
18. Krassas GE and Wiersinga WM (2006) Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 154: 777-780
19. Wiersinga WM and Bartalena L (2002) Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12: 855-860
20. Prummel MF et al. (1990) Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150: 1098-1101
21. Tallstedt L et al. (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326: 1733-1738
22. Bartalena L et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73-78
23. Gorman CA (1995) Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 80: 340-341
24. Tallstedt L et al. (1994) Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130: 494-497
25. Törring O et al. (1996) Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - prospective, randomized study. J Clin Endocrinol Metab 81: 2986-2993
26. Perros P et al. (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90: 5321-5323
27. Jensen BE et al. (2005) Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol 153: 15-21
28. Marcocci C et al. (1999) The course of Graves' ophthalmopathy is not influenced by near-total thyroidectomy: a case-control study. Clin Endocrinol 51: 503-508
29. Järhult J et al. (2005) Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15: 1157-1164
30. Moletti M et al. (2003 Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 13: 653-658
31. Ravzi S et al. (2006) What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 154: 783-786
32. Perros P et al. (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 42: 45-50
33. Mourits MP et al. (2000) Radiotherapy for Graves' orbitopathy; randomized placebo-controlled study. Lancet 355: 1505-1509
34. Prummel MF et al. (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 89: 15-20
35. Wiersinga WM (1996) Advances in medical therapy of thyroid-associated ophthalmopathy. Orbit 15: 177-186
36. Gerding MN et al. (2000) Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 52: 641-646
37. Lazarus JH et al. (2006) Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol [doi: 10.1136/bjo.2006.094607]
38. Kalmann R and Mourits MP (1999) Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Br J Ophthalmol 83: 463-465
39. Wakelkamp IMMJ et al. (2005) Surgical or medical decompression as a first line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol 63: 323-328
40. Kahaly GJ et al. (2000) Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized single blind trial. J Clin Endocrinol Metab 85: 102-108
41. Gerling J et al. (2003) Retrobulbar irradiation for thyroid associated orbitopathy: double blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 55: 182-189
42. Marcocci C et al. (2003) Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 88: 3561-3566
43. Wakelkamp IMMJ et al. (2004) Orbital irradiation for Graves' ophthalmopathy. Is it safe? A long-term followup study. Ophthalmology 111: 1557-1562
44. Prummel MF et al. (1989) Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321: 1353-1359
45. Kahaly G et al. (1996) Randomized trial of intravenous immunoglobulins versus prednisone in Graves' ophthalmopathy. Clin Exp Immunol 106: 197-202
46. Prummel MF et al. (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 342: 949-954
47. Gorman CA et al. (2001) A prospective randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 108: 1523-1534
48. Wémeau JL et al. (2005) Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 90: 841-848
49. Dickinson JA et al. (2004) Double-blind, placebocontrolled trial of octreotide long-acting release (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89: 5910-5915
50. Chang T-C and Lino S-L (2006) Slow-release lanreotide in Graves' opthalmopathy: a double blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest 29: 413-422
51. Stan MN et al. (2006) Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 91: 4817-4824
52. Marcocci C et al. (1991) Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 14: 853-860
53. Kahaly G et al. (1986) Cyclosporin and prednisone vs prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16: 415-422
54. Marcocci C et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, singleblind, randomized study. J Clin Endocrinol Metab 86: 3562-3567
55. Kahaly GJ et al. (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234-5240
56. Kauppinen-Mäkelin R et al. (2002) High dose intravenous methylprednisolone therapy versus oral prednisone for thyoid-associated ophthalmopathy. Acta Ophthalmol Scand 80: 316-321
57. Ohtsuka K et al. (2003) Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol 135: 285-290
58. Weissel M and Hauff W (2000) Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease [letter]. Thyroid 10: 521
59. Marino M et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14: 403-406
60. Salvi M et al. (2004) Onset of autoimmune hepatitis during intravenous therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 14: 631-634
61. LeMoli R et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid, in press
62. Boulos PR and Hardy I (2004) Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 15: 389-400
63. Bartley GB et al. (1996) Long-term follow-up of Graves' ophthalmopathy in an incidence cohort. Ophthalmology 103: 956-962
64. Finamor FE et al. (2004) Pentoxiphylline (PTX) - an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exopthalmometry in a prospective randomized trial. Eur J Ophthalmol 14: 277-283
65. Paridaens D et al. (2005) The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 19: 1286-1289
66. Salvi M et al. (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156: 33-40